ArticleBioorganic chemistry2025
Design, synthesis, and evaluation of quinoxaline-based survivin inhibitors for castration-resistant prostate cancer.
Article in Bioorganic chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Breaking the bonds: targeting protein dimerization for prostate cancer therapy.Endocrinology · 2026Review
- Novel quinoxaline-based survivin degraders overcome docetaxel-resistance in castration-resistant prostate cancer.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Survivin, a member of the Inhibitors of Apoptosis Protein (IAP) family, is a homodimer and plays a vital role in cell survival and cell cycle progression. Due to its unique expression pattern in nearly all cancers but not normal adult tissues, survivin has been regarded as an ideal anticancer drug target. Targeting its hydrophobic dimerization interface has recently resulted in novel survivin degraders that induce its degradation in the proteasome. One orally available degrader, LQZ-7I (7I), has a quinoxaline core linked to two 4-fluorobenzyl groups via two secondary amine bonds. In this study, we tested the hypothesis that the electron-withdrawing groups (EWGs) on the benzene rings facilitate the binding to survivin and increase cytotoxicity using a reiterative medicinal chemistry approach. This led to the identification of two promising 7I analogs, 7I10 and 7I14, with the same quinoxaline pharmacophore but more or stronger EWGs, 3,4,5-trifluoro and 4-trifluoromethyl groups, respectively. Their cytotoxic IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.